ninds ninds ninds |  
ninds   |   Bookmark & Share ninds
Profile Image

Clinical Neurocardiology Section

David S. Goldstein, M.D., Ph.D.

Senior Investigator

Clinical Neurocardiology Section, CNP
Building 10 Room 5N220
9000 Rockville Pike
10 Center Drive
MSC 1620
Bethesda MD 20892-1620
Office: (301) 496-2103
Lab: (301) 496-7832
Fax: (301) 402-0180
goldsteind@ninds.nih.gov

Dr. Goldstein graduated from Yale College and received an M.D.-Ph.D. in Behavioral Sciences from Johns Hopkins. After medical internship and residency at the University of Washington, he came to the NIH as a Clinical Associate in the NHLBI, obtaining tenure as a Senior Investigator in 1984. He joined the NINDS in 1990 to head the Clinical Neurochemistry Section and founded and directs the Clinical Neurocardiology Section, an Independent Section. He has received Yale's Angier Prize for Research in Psychology, the Laufberger Medal of the Czech Academy of Sciences, 2 NIH Merit Awards, the Founders Award of the Bakken Heart-Brain Institute, the Distinguished Investigator Award of the Society for Clinical and Translational Science, and the NIH Distinguished Clinical Teacher Award. He is author of more than 500 research articles and several books, including "Adrenaline and the Inner World: An Introduction to Scientific Integrative Medicine," ”Dysautonomias: A Handbook for Patients,” "Stress, Catecholamines, and Cardiovascular Disease," and "The Autonomic Nervous System in Health and Disease.”



Dr. Goldstein's research interests are in catecholamine systems, clinical autonomic disorders, and scientific integrative medicine. The Clinical Neurocardiology Section, which he founded and directs, carries out mainly patient-oriented research. The Section operates a renowned Clinical Neurochemistry Laboratory for assays of levels of catecholamines and their metabolites. Current research of the Section focuses on biomarkers and mechanisms of catecholamine depletion in Parkinson disease and related disorders.

A major new study by the Clinical Neurocardiology Section is on biomarkers of risk of Parkinson disease (PD). We call this the PDRisk study (NIH Protocol 09-N-0010). There are two main purposes of this study. The first purpose is to determine whether people who have characteristics that may be risk factors for PD have objective evidence—“biomarkers”—that the disease process is actually going on. The evidence we are looking for is loss of nerves and nerve cells that use particular chemicals, called catecholamines. PD patients typically have a loss of nerves and nerve cells that use the catecholamines dopamine and norepinephrine as chemical messengers. The second purpose is to determine whether people who have abnormal “biomarkers” actually develop PD during several years of follow-up.

For more information about our PDRisk study please visit our Protocol-specific website, https://pdrisk.ninds.nih.gov.



Clinical Protocol

  • Clinical Laboratory Evaluation of Primary Chronic Autonomic Failure ( 03-N-0004 )

  • Biomarkers of Risk of Parkinson Disease ( 09-N-0010 )

Staff Image
  • Glen Cook, M.D.
    Clinical Fellow
    Phone : (301) 451-1670
    Email : glen.cook@nih.gov

  • Courtney Holmes, C.M.T.
    Biologist
    Phone : (301) 496-7832
    Email : holmesc@ninds.nih.gov

  • Tereza Jenkins
    Secretary/Patient Care Coordinator
    Phone : (301) 496-1115
    Email : jenkinst@ninds.nih.gov

  • Yunden Jinsmaa, Ph.D.
    Contractor
    Phone : (304) 402-9486
    Email : jinsmaa.jinsmaa@nih.gov

  • Irwin Kopin, M.D.
    Scientist Emeritus
    Phone : (301) 496-4297
    Email : kopini@ninds.nih.gov

  • Sandra Pechnik, R.N.
    Research Nurse
    Phone : (301) 435-5166
    Email : pechniks@ninds.nih.gov

  • Patti Sullivan
    Biologist
    Phone : (301) 402-2052
    Email : psullivan1@ninds.nih.gov

  • 1) Goldstein DS. (2013)
  • Dysautonomias: A Handbook for Patients, (available from the Author)
  • 2) Goldstein DS. (2013)
  • Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.
  • Compr Physiol, 3, 1569-1610. (PMID 24265239).
  • 3) Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong G, Mash DC, Kopin IJ, Sharabi Y. (2013)
  • Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson disease.
  • J Neurochem, 123, 591-603. (PMID: 23786406).
  • 4) Goldstein DS. (2006)
  • Adrenaline and the Inner World: An Introduction to Scientific Integrative Medicine
  • Johns Hopkins University Press
  • 5) Eisenhofer G, Kopin IJ, Goldstein DS. (2004)
  • Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
  • Pharmacol Rev, 56, 331-349
  • 6) Goldstein DS, Eisenhofer G, Kopin IJ. (2003)
  • Sources and significance of plasma levels of catechols and their metabolites in humans
  • J Pharmacol Exp Ther, 305, 800-811
  • 7) David S. Goldstein, MD, PhD; Discussants: David Robertson, MD; Murray Esler, MD; Stephen E. Straus, MD; and Graeme Eisenhofer, PhD (2002)
  • Dysautonomias: Clinical Disorders of the Autonomic Nervous System
  • Ann Intern Med. 2002, 137, 756-7
  • 8) Goldstein DS, Smith LJ (2002)
  • The NDRF Handbook for Patients with Dysautonomias
  • Futura
  • 9) Goldstein DS, Holmes C, Dendi R, Bruce S, Li S-T (2002)
  • Orthostatic hypotension from sympathetic denervation in Parkinson’s disease
  • Neurology, 58, 1247-1255
  • 10) Lenders JWM, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. (2002)
  • Biochemical diagnosis of pheochromocytoma: Which test is best?
  • JAMA, 287, 1427-1434
  • 11) Goldstein DS (2001)
  • The Autonomic Nervous System in Health and Disease
  • Taylor & Francis
  • 12) Eisenhofer G, Lenders JWM, Linehan WM, Walther MM, Goldstein DS, Keiser HR (1999)
  • Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2
  • N Engl J Med, 340, 1872-1879
  • 13) Goldstein DS (1997)
  • On the dialectic between molecular genetics and integrative physiology: Toward a new medical science
  • Perspectives Biol Med, 40, 505-515
  • 14) Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ (1997)
  • Sympathetic cardioneuropathy in dysautonomias
  • N Engl J Med, 336, 696-702
  • 15) Goldstein DS, Lenders JWM, Kaler SG, Eisenhofer G. Catecholamine phenotyping: Clues to the diagnosis, treatment, and pathophysiology of neurogenetic disorders (1996)
  • Catecholamine phenotyping: Clues to the diagnosis, treatment, and pathophysiology of neurogenetic disorders
  • J Neurochem , 67, 1781-1790
  • 16) Goldstein DS (1995)
  • Stress, Catecholamines, and Cardiovascular Disease
  • Oxford Univ. Press

View/Hide All Publications